Navigation Links
Mylan Announces Intention to Purchase Remaining Interest in Matrix Laboratories and Delist Matrix from Indian Stock Exchanges
Date:3/26/2009

PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced its plans to purchase the remaining interest in Matrix Laboratories Limited from minority shareholders pursuant to a voluntary delisting offer. Mylan, through a wholly-owned subsidiary, currently owns approximately 71.2% of Matrix and controls more than 76% of its voting rights. The impact of the transaction is anticipated to be accretive to Mylan's 2009 earnings.

Mylan Vice Chairman and CEO Robert J. Coury commented: "Purchasing the remaining interest in Matrix and delisting it from the exchanges will provide Mylan an opportunity for enhanced flexibility and efficiencies in managing our global technical and commercial operations platform. This move represents another step toward achieving our goal of becoming the most efficient global generics and specialty pharmaceutical company in the industry. The transaction also would provide Matrix's public shareholders with an attractive near-term liquidity opportunity."

Mylan has approved an indicative acquisition price of up to Rs 150 per share. This price reflects a premium of 27% of the closing share price of Matrix on March 26, the last trading day before the announcement. It also represents a premium of 54% and 77% over Matrix's average share price during the last month and last six months, respectively.

If as a result of the delisting offer, the total promoter shareholding (including 4.97% shares held by the Indian promoter) exceeds 90% of all outstanding shares, Matrix will be delisted from the Bombay Stock Exchange (BSE) Limited and the National Stock Exchange (NSE) of India Limited. The delisting process is expected to take approximately 12 weeks subject to obtaining regulatory approvals. If Mylan acquires all remaining 45 million shares, the aggregate purchase price will total approximately $133 million. Mylan intends to fund the purchase using current cash balances.

The acquisition and delisting are conditional upon Mylan's acceptance of the exit price per share, which Mylan may accept or reject at its sole discretion, as well as receipt of any statutory or regulatory approvals.

This press release contains statements that constitute "forward-looking statements," including with regard to the planned share acquisition and delisting, the price per share, the transaction's impact on earnings, anticipated timing and the company's expectations for the future. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: unexpected regulatory or legal challenges; shareholders' decisions regarding pricing and selling their shares, including due to market fluctuations; Mylan's decision to reject the exit price per share; changes in economic and financial conditions affecting the company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's Form 10-K for the year ended Dec. 31, 2008, and its other reports filed with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for First Generic, Heat-Stable Version of HIV Protease Inhibitor
2. Mylans Matrix Receives WHO Approval for First Generic, Heat-Stable Version of HIV Protease Inhibitor
3. Mylan Announces Transition of Chief Financial Officer
4. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
5. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
6. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
9. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
10. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
11. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. ... will be included in the 2016 “Guide to America’s Top Plastic Surgeons” for ... the amalgamation of their education, experience, and professional associations. , One the ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Clarify Health ... has raised $6.0 million in an initial round of funding. The round was ... and their caregivers can receive far better care through the application of the ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... announce that we have been designated as a Cigna Infertility Center of Excellence. ... rigorous performance standards. , “It’s an honor to be designated a Cigna ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Research and Markets has announced the addition of ... Markets and Companies" to their offering. ... , , ... The market value of drug delivery technologies and the anticancer drugs ... according to organs involved and the types of cancer as well ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
Breaking Medicine Technology: